YIFAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.47 CNY | +3.92% |
|
+0.89% | -15.63% |
| 06-04 | Yifan Pharmaceutical Gets Nod to Register Phloroglucinol Injection | MT |
| 05-14 | Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.63% | 2.09B | C | ||
| +56.89% | 823B | C+ | ||
| +39.52% | 627B | B | ||
| -6.55% | 353B | C+ | ||
| +15.99% | 320B | B- | ||
| +7.92% | 295B | C+ | ||
| +13.74% | 239B | B+ | ||
| +13.83% | 220B | B- | ||
| -0.49% | 219B | A+ | ||
| +7.94% | 167B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002019 Stock
- Ratings Yifan Pharmaceutical Co., Ltd.
